A Congressional committee led by Senator Bernie Sanders is demanding solutions from pharmaceutical corporations on the excessive prices of bronchial asthma inhalers, in line with a report by The Hill.
Sanders and members of the Senate’s Well being, Training, Labor and Pensions (HELP) Committee, despatched letters to the CEOs of AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, and Teva Pharma, that are the 4 largest producers of inhalers, in line with The Hill. The report says Congress is demanding “data and paperwork on inside strategic communications, affected person help packages and the prices concerned within the manufacturing of inhalers.”
For instance, certainly one of AstraZeneca’s inhalers prices $645 within the U.S. however simply $49 within the UK. One in all Boehringer Ingelheim’s inhalers prices $489 within the US however simply $7 in France. GSK’s widespread Advair HFA prices $319 within the US however simply $26 within the UK.
The senators accused the producers of exploiting the regulatory system to make sure their merchandise don’t face competitors from generics, which will help drive down prices for sufferers. “There isn’t a motive for these merchandise to be so costly. The units have been accessible because the Nineteen Fifties and many of the medication they use have been in the marketplace for greater than 25 years,” the lawmakers famous.
Learn extra at www.thehill.com